OTCMKTS:CPHRFCipher Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.97 +0.01 (+1.05 %) (As of 07/16/2020 01:09 PM ET) Add Compare Share Today's Range$0.96Now: $0.97▼$0.9750-Day Range$0.87MA: $0.89▼$0.9652-Week Range$0.30Now: $0.97▼$1.22Volume4,200 shsAverage Volume4,354 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesSocial Media Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients. It also provides BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; and Ozenoxacin to treat adult and paediatric patients with impetigo. In addition, the company has various commercial and pipeline hospital products administered in the acute care setting. Its pipeline products include Dermadexin and Pruridexin for the treatment of common chronic conditions; CF101 for the treatment of plaque psoriasis and rheumatoid arthritis; DTR-001 that is in pre-clinical stage of development for the removal or reduction of the appearance of tattoos; and ASF-1096, an orphan drug indication for the treatment of anorectal indications. Cipher Pharmaceuticals Inc. has a licensing agreement with Synergy Pharmaceuticals Inc. for developing, marketing, distributing, and selling TRULANCE (plecanatide). The company was founded in 2004 and is headquartered in Mississauga, Canada.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingCipher Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Cipher Pharmaceuticals has a potential upside of 314.5% from its current price of $0.97.Amount of Analyst CoverageCipher Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCipher Pharmaceuticals has received 85 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCipher Pharmaceuticals has received 85 “underperform” votes. (Add your “underperform” vote.)Community SentimentCipher Pharmaceuticals has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cipher Pharmaceuticals and other stocks. Vote “Outperform” if you believe CPHRF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CPHRF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCipher Pharmaceuticals does not currently pay a dividend.Dividend GrowthCipher Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cipher Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 25.09% of the stock of Cipher Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.15 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CPHRF Previous SymbolNASDAQ:CPHR CUSIPN/A CIKN/A Webwww.cipherpharma.com Phone+1-905-6025840Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable OTC:CPHRF Rates by TradingView Receive CPHRF News and Ratings via Email Sign-up to receive the latest news and ratings for CPHRF and its competitors with MarketBeat's FREE daily newsletter. Cipher Pharmaceuticals (OTCMKTS:CPHRF) Frequently Asked Questions How has Cipher Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Cipher Pharmaceuticals' stock was trading at $0.6097 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CPHRF shares have increased by 58.3% and is now trading at $0.9650. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Cipher Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cipher Pharmaceuticals. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc (OTCMKTS:CPHRF) announced its earnings results on Thursday, May, 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.06. The business earned $9.10 million during the quarter, compared to analysts' expectations of $10.87 million. View Cipher Pharmaceuticals' earnings history. What price target have analysts set for CPHRF? 2 brokers have issued 12 month price objectives for Cipher Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Cipher Pharmaceuticals' share price to reach $4.00 in the next year. This suggests a possible upside of 314.5% from the stock's current price. View analysts' price targets for Cipher Pharmaceuticals. Has Cipher Pharmaceuticals been receiving favorable news coverage? News headlines about CPHRF stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cipher Pharmaceuticals earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news about Cipher Pharmaceuticals. Who are some of Cipher Pharmaceuticals' key competitors? Some companies that are related to Cipher Pharmaceuticals include 1933 Industries (TGIF), Abacus Health Products (ABAHF), Acreage (ACRGF), Alliance Growers (ACG), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Biome Grow (BIO), Blueberries Medical (BBM), Canbiola (CANB), Cannara Biotech (LOVE), Cansortium (CNTMF), Charlotte's Web (CWBHF), Choom (CHOOF), CLS Holdings USA (CLSH) and Cosmos (COSM). View all competitors. Who are Cipher Pharmaceuticals' key executives? Cipher Pharmaceuticals' management team includes the following people: Mr. Robert D. Tessarolo, Pres, CEO & Director (Age 51)Mr. Stephen L. Lemieux, CFO & Sec.Mr. Chris Watters, VP of Corp. Devel.Dr. Diane Gajewczyk, VP of Scientific & Medical AffairsMr. Norman Evans, Consultant (Age 64) What is Cipher Pharmaceuticals' stock symbol? Cipher Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CPHRF." How do I buy shares of Cipher Pharmaceuticals? Shares of CPHRF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cipher Pharmaceuticals' stock price today? One share of CPHRF stock can currently be purchased for approximately $0.97. What is Cipher Pharmaceuticals' official website? The official website for Cipher Pharmaceuticals is www.cipherpharma.com. How can I contact Cipher Pharmaceuticals? Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company can be reached via phone at +1-905-6025840. This page was last updated on 7/16/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
